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A B S T R A C T   
Opioid signaling controls the activity of the brain’s reward system. It is involved in signaling the hedonic effects 
of rewards and has essential roles in reinforcement and motivational processes. Here, we focused on opioid 
signaling through mu and delta receptors on dopaminoceptive neurons and evaluated the role these receptors 
play in reward-driven behaviors. We generated a genetically modified mouse with selective double knockdown 
of mu and delta opioid receptors in neurons expressing dopamine receptor D1. Selective expression of the 
transgene was confirmed using immunostaining. Knockdown was validated by measuring the effects of selective 
opioid receptor agonists on neuronal membrane currents using whole-cell patch clamp recordings. We found that 
in the nucleus accumbens of control mice, the majority of dopamine receptor D1-expressing neurons were 
sensitive to a mu or delta opioid agonist. In mutant mice, the response to the delta receptor agonist was blocked, 
while the effects of the mu agonist were strongly attenuated. Behaviorally, the mice had no obvious impairments. 
The mutation did not affect the sensitivity to the rewarding effects of morphine injections or social contact and 
had no effect on preference for sweet taste. Knockdown had a moderate effect on motor activity in some of the 
tests performed, but this effect did not reach statistical significance. Thus, we found that knocking down mu and 
delta receptors on dopamine receptor D1-expressing cells does not appreciably affect some of the reward-driven 
behaviors previously attributed to opioid signaling.   
1. Introduction 
Opioid signaling controls the activity of the brain’s reward system, 
acting as a regulator of the mesolimbic system, both at the level of 
dopamine neurons in the midbrain and dopaminoceptive medium spiny 
neurons in the striatum. It is now well established that mu receptor 
agonists inhibit GABAergic signaling in the ventral midbrain, which 
leads to an increase in dopamine neuron activity and is critical for the 
euphoric and reinforcing effects of opioids (Fields and Margolis, 2015). 
Conversely, the role of opioid signaling in dopaminoceptive neurons (i. 
e., neurons that receive dopamine inputs), particularly striatal medium 
spiny neurons, remains only partly understood. It has been reported that 
the activation of mu or delta opioid receptors in discrete areas of the 
nucleus accumbens of the striatum induces hedonic reactions and pro-
motes the intake of palatable food or drink (e.g. (Castro and Berridge, 
2014; Peciña and Berridge, 2005; Zhang and Kelley, 1997),). These 
observations led to an influential model linking opioid signaling through 
mu and delta receptors in the nucleus accumbens to the “liking” 
component of reward and separating it from dopamine signaling, 
involved primarily in motivational processes, or the “wanting” compo-
nent of reward (Berridge et al., 2009; Wise, 2004). Nevertheless, some 
evidence has indicated that such elegant separation of roles may be too 
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simplistic. The reported reinforcing effects of direct mu opioid receptor 
agonist injection into the striatum on conditioned place preference in 
rats appear to be inconsistent, although anatomical differences have 
been suggested as a potential explanation for these discrepancies (Bal-
s-Kubik et al., 1993; Castro and Berridge, 2014). Intrastriatal injections 
of delta agonists have been observed to have no effect on place prefer-
ence (Bals-Kubik et al., 1993). The complete loss of mu opioid receptors 
abolishes the rewarding effects of morphine in mice (Matthes et al., 
1996), and the reintroduction of mu receptor expression to direct 
pathway medium spiny neurons of the striatum is sufficient to restore 
morphine-conditioned place preference (Cui et al., 2014). It has also 
been reported that the selective deletion of mu opioid receptors in 
forebrain GABAergic neurons (including those in the striatum) spares 
opioid-conditioned place preference but affects motivation to 
self-administer heroin or obtain palatable food (Charbogne et al., 2017). 
To add further complexity, it appears that opioid signaling in the fore-
brain may play different roles depending on the type of reward, as the 
same mutation completely abolishes alcohol-conditioned place prefer-
ence (Hamida et al., 2019). It should also be noted that mu (but not 
delta) opioid signaling in the nucleus accumbens has been implicated in 
the rewarding effects of social interaction (e.g. Trezza et al., 2011). 
Thus, while the majority of reports have implicated opioid signaling in 
the striatum in the control of reward-driven behaviors, there is no 
consensus on the actual mechanisms involved. 
All types of opioid receptors are expressed in the striatum (including 
the nucleus accumbens), and their mRNA and protein levels follow 
discrete distribution patterns (Le Merrer et al., 2009; Mansour et al., 
1995; Svingos et al., 1997). Mu opioid receptor mRNA and protein are 
mainly present, and ligand binding mainly occurs in striatal patches or 
striosomes (Crittenden and Graybiel, 2011). Conversely, delta opioid 
receptor mRNA levels are relatively low, but the delta opioid receptor is 
the most abundant opioid receptor protein in the striatum. It has been 
reported that delta opioid receptors are present mainly on indirect 
pathway neurons that project to the intermediate nuclei in the basal 
ganglia, while mu receptors are expressed both on direct and indirect 
pathway medium spiny neurons; however, the reported fractions of 
neurons expressing these receptors vary considerably (Ambrose et al., 
2006; Banghart et al., 2015; Oude-Ophuis et al., 2014). Recent 
single-cell transcriptome analyses of the whole brain identified a sub-
class of neurons that express dopamine receptor D1 but have no or very 
low delta opioid receptor expression as well as subtypes of cells that 
express the D1, mu and delta receptors (Zeisel et al., 2018). Together, 
these data suggest that the expression of opioid receptors in the same 
neuronal population may be variable, and there is no clear agreement 
among reports based on different methodologies. 
Here, we investigated the role of mu and delta opioid receptor- 
dependent signaling in D1-expressing neurons in reward-driven behav-
iors. We generated a novel mouse model with selective knockdown of 
both receptors by means of RNA interference. The main rationale for 
targeting both receptors was that they are mainly activated by the same 
ligands – enkephalins – and trigger intracellular signaling cascades 
initiated by Go/i proteins (Gendron et al., 2016; Williams et al., 2013). 
Therefore, while these receptors may potentially have different roles in 
the striatum, this is mainly due to their presence on different cell types; 
on the other hand, their effects in a single type of neuron are highly 
similar. Thus, the elimination of one of these receptors could be 
compensated for by the effects of the other. We found that while 
knockdown reduced or abolished the activity of the mu and delta re-
ceptors, no significant effects on reward-driven behaviors were 
observed. 
2. Materials and methods 
2.1. Animals 
2.1.1. Oprd1/Oprm1D1− KD mouse strain 
Short hairpin RNAs against the mu and delta receptors were designed 
using BLOCK-IT RNAi Designer software (Invitrogen, USA). The se-
quences of the 21-nt fragments complementary to the target mRNAs 
were GCTGCCCTTTCAGAGTGTTAA (Oprm1-1), CCTTTGGAAA-
CATCCTCTGCA (Oprm1-2), GCTGGTGATTCCTAAACTGTA (Oprd1-1) 
and CGCCTTGAGATAACATCGGGT (Oprd1-2). Synthetic oligonucleo-
tides were cloned into the GW/EmGFP-miR vector (Invitrogen), which 
contains sequences derived from miR-155 (see Fig. 1A for summary). A 
construct harboring 4 hairpins was recombined into a bacterial artificial 
chromosome (BAC; RP24–179E13; Children’s Hospital Oakland 
Research Institute, USA) containing the mouse Drd1a gene. The BAC was 
purified, the vector sequences were removed, and the transgene was 
injected into the pronuclei of fertilized oocytes from SWR/J mice. 
Mutant mice were congenically bred onto the C57BL/6N background 
(>8 generations of backcrosses before the start of the experiments). 
Transgenic animals were genotyped by PCR using primers with the 
sequences ACGTAAACGGCCACAAGTTC and ACGTAAACGGCCA-
CAAGTTC (amplicon size 180 bp), which target the eGFP-encoding 
sequence. Additionally, each genotyping reaction also included posi-
tive control primers with the sequences CCATTTGCTGGAGTGACTCTG 
and TAAATCTGGCAAGCGAGACG (amplicon size 370 bp). The PCR 
conditions were as follows: 3 min of denaturation at 95 ◦C, followed by 
40 cycles of 30 s at 95 ◦C, 30 s at 58 ◦C, and 60 s at 72 ◦C. 
The experiments were performed on adult Oprd1/Oprm1D1− KD mice 
and their wild-type littermates aged 7–17 weeks at the beginning of the 
procedures. The exception was the social-conditioned place preference 
procedure, which was started when mice reached the age of 4 weeks. 
Male mice were used for all experiments except the IntelliCage experi-
ment. The animals were housed 2-6 per cage in rooms with a controlled 
temperature of 22 ± 2 ◦C under a 12/12-h light-dark cycle with ad 
libitum access to food and water. The animals were handled for 5–7 days 
before the beginning of the experimental procedures, with the exception 
of the social-conditioned place preference where juvenile males were 
handled for a single day. The experiments were conducted during the 
dark phase, except for the light-dark box test and morphine-conditioned 
place preference test, which were conducted during the light phase. The 
saccharin preference test and the IntelliCage experiment were con-
ducted over one or several days. 
All behavioral procedures were approved by the II Local Bioethics 
Committee in Krakow (permit numbers 1000/2012, 224/2016, and 
264/2019) and conducted in accordance with the European Commu-
nities Council Directive 2010/63/EU. 
2.1.2. Quantitative PCR analysis of Oprm1 and Oprd1 transcript 
abundance 
Preliminary silencing efficiency was validated in CHO-K1 cells 
cotransfected with plasmids encoding opioid receptors and plasmids 
encoding the miRNA cassette. Constructs were tested separately using 
GW/EmGFP-miR vectors expressing either the Oprd1-1 and Oprd1-2 or 
Oprm1-1 and Oprm1-2 hairpins. Cells were cotransfected with a vector 
expressing mRNAs corresponding to the targeted receptors. The assays 
were performed in triplicate. Two days after transfection, the cells were 
harvested, and RNA was isolated using phenol extraction (Chomczynski 
and Sacchi, 2006). cDNA synthesis was performed using the Omniscript 
RT Kit (Qiagen, Germany) and Oligo(dT)12-18 primers (Invitrogen, 
USA). For quantitative PCR analysis, we used the TaqMan Gene 
Expression Assays (Applied Biosystems, USA) Mm00443063_m1 
(Oprd1), Mm01188089_m1 (Oprm1), and Mm00446968_m1 (Hprt1) and 
a CFX96 Real-Time system (Bio-Rad, USA). Relative transcript abun-
dances were quantified based on the threshold cycle value and 
normalized to the value obtained for Hprt1 (ΔCt). 
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Analysis of the effects of transgene expression on Oprm1 and Oprd1 
transcript abundance was performed on 6 Oprd1/Oprm1D1− KD [Tg/0] 
and 6 controls ([0/0] littermates). Mice of both sexes were used in this 
experiment (6 females and 6 males, equally split between genotypes). 
Animals were killed by cervical translocation, brains were extracted and 
fixed overnight in RNAlater (at 4 ◦C on a rocking platform), and then 
they were sliced into 125-μm coronal sections on a vibratome (VT1200, 
Leica, Germany). The dorsal striatum and the nucleus accumbens were 
excised separately using needles under a Stemi DV4 binocular (Zeiss, 
Germany) from sections corresponding to brain areas +1.94 mm to 
+0.6 mm and +1.8 mm to +0.1 mm from bregma, respectively (Paxinos 
and Franklin, 2001). Isolation of RNA, cDNA synthesis and quantitative 
PCR were performed following the same procedure as described in the 
case of transfected cells. 
2.1.3. Transgene expression 
The expression of the transgene was assessed by analyzing the 
coexpression of the eGFP protein with the miR precursor by immuno-
staining. Both immunohistochemistry and immunofluorescence were 
used. Briefly, the animals were perfused with 4% paraformaldehyde in 
phosphate-buffered saline, and the brains were removed and postfixed 
overnight. For immunochemistry, the brains were sliced into 40-μm 
sections in the coronal plane on a vibratome (Leica, Germany), the 
sections were blocked with goat/pig serum hybridized with an anti-GFP 
antibody (rabbit, Thermo Fisher Scientific, A-11122, 1:500), and then 
the signal was developed using the Rabbit Vectastain ABC HRP kit and 
diaminobenzidine substrate (Vector Inc., USA). Images were acquired 
using an Aperio ScanScope CS device (Leica, Germany). 
For immunofluorescence, perfused brains were either prepared as 
above (Fig. 2B) or frozen in 30% (w/v) saccharose and sliced into 40-μm 
sections on a cryostat (Leica, Fig. 2C). The sections were stained with an 
anti-GFP antibody (chicken, Abcam, ab13970, 1:10,000 or 1:1000, 
Fig. 2C and B, respectively) alone or together with a rabbit anti-ppEnk 
antibody (Neuromics, RA14124-50; 1:1000). The following secondary 
antibodies were used: Alexa Fluor 488-conjugated goat anti-chicken IgY 
(H + L) (Invitrogen, A-11039, 1:1000) and Alexa Fluor 555-conjugated 
donkey anti-rabbit (Invitrogen, A-31572, 1:1000 or Thermo Fisher, #A- 
21428 1:500 Fig. 2C and B, respectively). Sections were mounted on 
Superfrost + microscope slides. Fluorescence images were acquired 
using an LSM700 Zeiss or a TCS SP8 WLL Leica confocal microscope 
(Fig. 2C and B, respectively). 
2.2. Whole-cell patch clamp activity recordings 
2.2.1. Brain slice preparation 
Mice (6- to 10-week-old males) were decapitated under isoflurane 
(Aerrane, Baxter) anesthesia. Coronal brain slices (250-μm thick) con-
taining the nucleus accumbens were cut on a vibratome (VT 1000S Leica 
Fig. 1. Generation of the Oprd1/Oprm1D1-KD mouse strain. (A) Schematic representation of the construct used to generate the mouse strain. (B) Summary of the 
knockdown efficiency results in CHO-K1 cells. The results show that the levels of Oprm1 or Oprd1 mRNA fragments were normalized after the cells were 
cotransfected with a construct expressing the targeted receptor fragment together with a construct expressing corresponding hairpins or a control hairpin. (C) 
Relative abundance of the Oprm1 and Oprd1 transcripts in the dorsal striatum and nucleus accumbens of Oprd1/Oprm1D1− KD mice (red) and control animals (black). 
The data are presented as the mean ± SEM. 
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Fig. 2. Transgene expression in Oprd1/ 
Oprm1D1-KD mice. (A) The micrograph shows 
immunological staining of GFP encoded by the 
transgene. The images on the right are mag-
nifications of the selected areas. Abbrevia-
tions: Cg – cingulate cortex, IL – infralimbic 
cortex, DP – dorsal peduncular cortex, AcbC – 
nucleus accumbens core, AscSh – nucleus 
accumbens shell. (B) Micrographs show the 
immunofluorescence staining of the striatum 
in coronal sections, with approximate distance 
from bregma indicated in the top left corners. 
(C) The micrographs of the nucleus accum-
bens show fluorescent immunostaining for 
GFP and preproenkephalin (ppEnk) and the 
composite image.   
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Microsystems, Germany). The slices were prepared from brain tissue 
submerged in ice-cold cutting artificial cerebrospinal fluid (ACSF) con-
taining (in mM) 92 NaCl, 30.0 NaHCO3, 1.25 NaH2PO4, 10.0 MgSO4, 2.5 
KCl, 0.5 CaCl2, 20.0 HEPES, 5.0 sodium ascorbate, 3.0 sodium pyruvate, 
2.0 thiourea and 10 glucose and were continuously bubbled with a 
mixture of 95% O2 and 5% CO2, pH 7.3–7.4, osmolarity 290-300 mos-
mol/kg. After cutting, the slices were immediately transferred to an 
incubation chamber filled with normal ACSF containing (in mM) 124 
NaCl, 26 NaHCO3, 1.25 NaH2PO4, 1 MgSO4, 4.5 KCl, 1.8 CaCl2 and 10 
glucose at 32 ± 0.2 ◦C. The tissue was incubated for at least 120 min 
before electrophysiological recordings. 
2.2.2. Cell visualization and cell identity confirmation 
Nucleus accumbens neurons were visualized with an upright mi-
croscope (Zeiss Axio Examiner A1 microscope, Zeiss, Germany) using 
video-enhanced infrared differential interference contrast (DIC) and 
fluorescence optics. Individual neurons were visualized using a 40 ×
water immersion lens. Dopamine receptor D1-expressing cells were 
identified based on the expression of GFP (KD animals) or tdTomato 
(control animals, (Ade et al., 2011)). GFP was excited at 455 nm, and 
tdTomato was excited at 530 nm by LED illumination (Zeiss Colibri). 
2.2.3. Whole-cell patch-clamp recordings 
Whole-cell current- and voltage-clamp recordings were made using 
the SEC-05X amplifier (NPI, Tamm, Germany). Signals were filtered at 3 
kHz and digitized at 20 kHz using a Micro1401 converter (Cambridge 
Electronic Design (CED), Cambridge, UK) with Signal and Spike2 soft-
ware (CED, UK). Patch micropipettes (7-9 MΏ) were pulled from boro-
silicate glass capillaries (Sutter Instrument, Novato, USA) using the 
Sutter Instrument P97 puller. The internal pipette solution contained (in 
mM) 125 K-gluconate, 20 KCl, 2 MgSO4, 10 HEPES, 4 Na2-ATP, 0.4 Na- 
GTP, 5 EGTA and 0.05% biocytin, osmolarity 290–300 mosmol/kg, pH 
7.2–7.3. A liquid junction potential of +12.4 mV was calculated, and the 
data were corrected for this value. 
To characterize the basic electrophysiological properties of D1 neu-
rons, recordings were performed in normal ACSF. The membrane po-
tential of the recorded neurons was held at − 75 mV by continuous 
current injections, and voltage responses to rectangular current steps 
(500 ms in duration, − 140 pA to +240 pA, 10-pA increments, with 5-s 
intervals between steps) and depolarizing current ramp (0.1–1 nA) 
were recorded. The membrane resistance, time constant and capacitance 
were measured from the voltage response to a − 140 pA hyperpolarizing 
pulse. The excitability of the recorded neurons was examined using 
depolarizing current pulses from +10 pA to +240 pA, and for each cell, 
the number of action potentials was plotted against the intensity of the 
injected current. Action potential (AP) parameters, specifically the AP 
threshold, amplitude, 10-90 rise time, half width, AHP minimum and 
action potential peak time to AHP minimum time (AP peak to AHP), 
were measured for the first action potential evoked by the minimal 
depolarizing current step. The rheobase was defined as the minimal 
current necessary to induce an action potential and was determined 
using a current ramp protocol. Next, to characterize current-voltage 
relationships, cells were voltage-clamped at a command potential of 
− 75 mV, and recordings were performed in the presence of 0.5 μM 
tetrodotoxin. Voltage steps from − 120 mV to +10 mV (500 ms in 
duration, 10-mV increments) were delivered every 3 s, and steady-state 
current responses were measured. 
To verify the presence of mu and delta opioid receptors on the 
membranes of D1-expressing neurons, cells were voltage-clamped at a 
command potential of − 65 mV. All recordings were performed in 
normal ACSF containing tetrodotoxin (0.5 μM). After obtaining stable 
whole-cell current recordings for at least 15 min, the selective mu opioid 
receptor agonist DAMGO (1 μM) or the selective delta opioid receptor 
agonist DPDPE (1 μM) was added to ACSF-perfused slices. Recordings 
lasted for at least 25 min following batch application of the drugs. 
2.2.4. Statistical analysis 
The values are given as the means ± SEM. In all experiments, p <
0.05 was considered significant. All datasets were tested for normal 
distribution, and outliers were excluded from the analysis (ROUT 
method, Q = 5%). The firing characteristics of the recorded neurons 
were analyzed by linear regression. Statistical significance between 
groups was determined using either Student’s t-test or the Mann- 
Whitney test when applicable. Data analysis was performed using 
GraphPad Prism for Windows. A recorded neuron was classified as 
responsive to a drug if the whole-cell current of the neuron after drug 
application differed from the baseline by more than three standard 
deviations. 
2.3. Behavioral procedures 
Behavior was recorded using a Basler (ac1300 – 60 gm) camera and 
EthoVision 11.5 software (Noldus, The Netherlands). The experimenter 
was blinded to the genotypes of the animals tested. 
2.3.1. Open field test 
Walking initiation and open field exploration were measured during 
the adaptation period before the social interaction test. The mice were 
introduced to a novel transparent plastic cage (55 × 37.5 cm x 20.5 cm 
high) containing 0.5 cm of bedding. The latency to leave a 17 × 17-cm 
square (outlined digitally) was used as a measure of walking initiation. 
Latencies were measured manually from video recordings with BORIS 
software (Friard and Gamba, 2016). Leaving the square was defined as 
putting all four paws outside the square. The distance moved during the 
30-min habituation period was measured using EthoVision 11.5 soft-
ware (Noldus). 
2.3.2. Light-dark box test 
The test was performed in a two-chamber apparatus (each chamber 
was 18 × 16 × 20 cm high). The light compartment was brightly lit (430 
lux), and the dark compartment was dimly lit (20 lux). The animals were 
placed in the dark compartment and allowed to freely explore the 
apparatus for 5 min. 
2.3.3. Social interaction test 
Partners (9- to 10-week-old male C57BL/6N mice, Charles River 
Laboratories, Germany) were habituated to our laboratory facilities for 
at least one week prior to the experiments. Focal animals were habitu-
ated to the test cage for 30 min before the test (55 × 37.5 × 20.5 cm, 
containing 0.5 cm of bedding). Immediately after habituation, the 
partner animal was placed in the cage, and the mice were allowed to 
interact for 10 min. Control animals were exposed to a novel object 
instead of a novel mouse. Aspen gnawing blocks (4 × 4 × 5 cm) were 
used as the novel objects. The blocks were identical in shape and size to 
the blocks in the home cages of the mice but differed in smell. Time in 
proximity was measured from video recordings with EthoVision 11.5 
software (Noldus). Proximity was defined as < 8 cm between body 
centers. 
2.3.4. Saccharin preference in the home cage 
Saccharin preference was assessed as described previously (Jastr-
zębska et al., 2016). Briefly, individually housed animals had 24-h ac-
cess to two 25-ml graduated drinking bottles. One bottle was filled with 
water, and the other bottle was filled with 0.1% saccharin solution. Food 
was provided ad libitum on the cage floor. 
2.3.5. Saccharin preference with delay discounting 
The test was performed in an IntelliCage (New Behavior, 
Switzerland), which allows for long-term monitoring of up to 15 mice 
living in a group with minimal interference from the experimenters. 
Mouse behavior was monitored using RFID chips (UNO PICO ID, Ani-
maLab, Poznań, Poland). The cage consisted of a housing area and four 
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operant chambers (situated in the corners of the cage) equipped with 
sensors. The operant chambers (later referred to as “corners”) were 
accessible by only one animal at a time. Each of the corners allowed 
access to two bottles through a guillotine door. The experiment con-
sisted of two phases: the adaptation phase (4 days) and the test phase (30 
days). During adaptation, the mice had free access to water in all cor-
ners. During the test, the mice were provided 0.1% saccharin solution in 
two of the corners. The guillotine door closed 10 s from the first lick or 
immediately after the mouse left the corner. The delay from the moment 
the mouse was detected in the corner until the doors opened increased 
from 0.5 to 35 s every 48 h (an initial delay of 0.5 s lasted for 96 h). The 
positions of the saccharin and water bottles were exchanged every 24 h. 
2.3.6. Morphine-conditioned place preference 
The test was conducted in automatic conditioned place preference 
(CPP) cages with three compartments (ENV-256C, Med Associates Inc., 
USA). One of the side compartments had black walls and a white floor, 
while the other had white walls and a black floor. On the first day of the 
procedure, the mice were habituated to the apparatus for 5 min (the 
floor was covered with white paper). On the second day, a pretest was 
conducted; the mice were placed in the central compartment and 
allowed to freely explore the whole apparatus for 20 min. On condi-
tioning days, the mice received an i.p. injection of either morphine (10 
mg/kg every other day) or saline and were immediately placed in one of 
the compartments for 40 min. The pairing of the compartment with 
morphine injection was biased, i.e., the mice were assigned to the 
compartment that was initially less preferred. The conditioning phase 
lasted eight days and was followed by a posttest, which was performed 
in the same manner as the pretest, on the ninth day. 
2.3.7. Social-conditioned place preference 
The procedure was performed as previously described, with modi-
fications (Dölen et al., 2013; Panksepp and Lahvis, 2007). Before the 
test, the animals were housed in groups of 2–6 on aspen shavings with 
aspen gnawing blocks (context A). The test consisted of three phases: the 
pretest, conditioning phase, and posttest (Fig. 7A). During the pretest, 
the animals were placed in a custom-made plastic cage (40 × 40 × 30 cm 
high) divided into two identical compartments by a transparent plastic 
wall with a 5 x 5-cm opening at the base. Each compartment contained a 
type of novel bedding; cellulose (Biofresh Performance Bedding, Ab-
sorption Corp, USA, 1/8′ pelleted cellulose), beech (P.P.H. “WO-JAR”, 
Poland, Trociny bukowe przesiane gat. 1), or spruce (LIGNOCEL® FS 14, 
J. Rettenmaier and Sohne, Germany), and a gnawing block different 
from the one in the home cage in size and/or shape (contexts B and C). 
The mice were allowed to freely explore the cage for 30 min. The 
amount of time spent in each compartment was measured by EthoVision 
XT 11.5 software (Noldus, The Netherlands). After the pretest, the mice 
were returned to their home cages (context A). The next day, the mice 
were assigned to undergo social conditioning (housing with cage mates) 
for 24 h in one of the contexts used in the pretest followed by 24 h of 
isolate conditioning (single housing) on the other type of bedding. Two 
experiments were performed on separate groups of animals. In the first 
experiment, beech and spruce were used. Since all mice showed a 
preference for beech over spruce, spruce was chosen as the social 
bedding. In the second experiment, beech and cellulose were used. The 
mice showed no preference between these beddings, and the assignment 
of contexts was random (unbiased design). The results of the two ex-
periments were pooled. Conditioning was repeated for 6 days (3 days in 
each context, alternating every day). The posttest was performed in the 
same manner as the pretest. The rewarding effects of the social context 
were measured by comparing the time spent in the social context during 
the posttest to the time spent in the social context during the pretest. 
3. Results 
3.1. Generation of Oprd1/Oprm1D1− KD mice 
The strain was generated following the general outline of the method 
described by (Novak et al., 2010). The transgene harbors a sequence 
encoding eGFP for easy detection of expression and two hairpins against 
each of the targeted sequences, the mu and delta opioid receptors 
(Fig. 1A). We first tested the knockdown efficiency in the CHO-K1 cell 
line and found average reductions of 60 and 80% in the abundance of 
the mRNA sequences corresponding to mu and delta receptors, respec-
tively (Fig. 1B). These measurements were based on triplicates and were 
used solely for the purpose of preliminary validation of the selected 
synthetic miRs. Transgenic mice were generated by injecting the trans-
gene construct (without the vector cassette) into fertilized oocytes. The 
offspring were screened for the presence of the transgene, and two 
founder lines were established. The line with higher transgene levels 
was selected for further experiments. To assess the effects of transgene 
expression, we measured the abundance of the Oprm1 and Oprd1 tran-
scripts in the dorsal striatum and nucleus accumbens of Opr-
d1/Oprm1D1− KD [Tg/0] mice (Fig. 1C). There was a ~35% decrease in 
the abundance of the Oprm1 transcript in both parts of the striatum, 
while the abundance of Oprd1 mRNA was not appreciably reduced. 
Analysis of GFP expression by staining with antibodies showed a 
pattern that was consistent with the known distribution of dopamine 
receptor D1 (Fremeau et al., 1991) (Fig. 2A and B). The strongest signal 
was observed in areas corresponding to the striatum, including the nu-
cleus accumbens and olfactory tubercle, and slightly weaker staining 
was also present in the deeper layers of the cortex and discrete areas of 
the septum. In the immunofluorescence staining, the signal appeared 
stronger in the striatum compared to other areas (Fig. 2B). In the nucleus 
accumbens, the expression of GFP and preproenkephalin exhibited a 
degree of overlap (Fig. 2C), which is again consistent with D1 receptors 
being mainly expressed on the neurons of the direct pathway equivalent 
in the nucleus accumbens (Gangarossa et al., 2013; Kupchik et al., 
2015). 
3.2. Whole-cell patch clamp recordings of activity in response to opioid 
antagonist treatment 
To characterize the influence of selective double knockdown of the 
mu and delta opioid receptors on the electrophysiological properties of 
D1 receptor-expressing neurons in the nucleus accumbens core, we used 
Oprd1/Oprm1D1− KD [Tg/0] mice as the KD group and D1-tdTomato mice 
[Tg/0] as the control group. Only neurons expressing tdTomato (control 
group, (Ade et al., 2011)) or GFP (KD group) were recorded (Fig. 3A and 
B). In total, 32 neurons from the control group and 26 from the KD group 
were included in the analysis. Whole-cell recordings revealed that mu 
and delta opioid receptor knockdown did not influence the shape of the 
action potentials of the examined neurons (Fig. 3C). Subsequent statis-
tical analysis did not reveal any differences in the measured AP pa-
rameters (action potential threshold, amplitude, 10-90 rise time, half 
width, and AHP minimum and AP peak to AHP, Table 1). Double 
knockdown of the mu and delta opioid receptors also did not influence 
the membrane resistance, capacitance or time constant of the recorded 
neurons (Fig. 3D, E, F). The excitability of nucleus accumbens neurons 
was determined by testing the relationship between the firing rate and 
the intensity of the injected current (Fig. 3G). The firing characteristics 
of the recorded neurons were fitted by linear regression (Fig. 3H), and 
the parameters did not differ between the groups. The mean gain and the 
threshold current were not affected by mu and delta opioid receptor 
knockdown (gain: 145.6 ± 7.35 Hz/pA in the control group and 132.0 ±
8.93 Hz/pA in the KD group, t(39) = 1.187, p = 0.243; threshold cur-
rent: 0.13 ± 0.008 nA in the control group and 0.11 ± 0.016 nA in the 
KD group; t(39) = 1.003, p = 0.322). Current-voltage relationships (I-V 
curves) were plotted using measurements of steady-state currents in 
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response to a series of incremental voltage steps recorded in ACSF 
containing tetrodotoxin. Two-way repeated measures ANOVA revealed 
no significant differences in the current responses of KD and control 
neurons (main effect of treatment, F(1,56) = 0.469, p = 0.496; Fig. 3I). 
To validate the lack of functional mu opioid receptor expression in 
the D1-expressing neurons of Oprd1/Oprm1D1− KD mice, we bath-applied 
the selective mu opioid receptor agonist DAMGO (1 μM) and recorded 
the whole-cell currents (− 65 mV command potential) of D1-expressing 
cells in slices from KD and control mice. DAMGO induced a reversible 
outward current that exceeded the baseline current value by three 
standard deviations in 9 of 12 voltage-clamped control neurons (Fig. 4A 
and B). Statistical analysis of the DAMGO-induced current amplitude in 
all examined neurons showed that in control cells, DAMGO application 
induced a statistically significant change in the recorded whole-cell 
current (mean whole-cell current at baseline: 0.23 ± 0.02 nA; mean 
whole-cell current during DAMGO application: 0.25 ± 0.02 nA; t(11) =
4.671, p = 0.0007; Fig. 4B). DAMGO application produced a reversible 
outward current, greater than the baseline current value by three stan-
dard deviations, in only 2 of 11 recorded KD neurons (Fig. 4C, D, E). 
Statistical analysis of the DAMGO-induced current amplitude in all 
examined cells showed that in KD neurons, DAMGO did not induce a 
statistically significant alteration in the whole-cell current (mean whole- 
cell current at baseline: 0.23 ± 0.03 nA; mean whole-cell current during 
DAMGO application: 0.24 ± 0.03 nA; t(10) = 2.091, p = 0.063; Fig. 4D). 
Subsequent comparison of the DAMGO-induced whole-cell current in 
KD and control neurons showed that the mu opioid receptor agonist 
Fig. 3. Passive and active membrane properties of nucleus accumbens core neurons expressing D1 receptor from control and Oprd1/Oprm1D1-KD (KD) 
mice. (A) Infrared differential interference contrast (note the presence of the recording pipette) and (B) fluorescence images of nucleus accumbens core neurons 
expressing mCherry. (C) Typical current stimulus evoked action potentials recorded from neurons from control and KD mice. Comparison of the (D) resistance, (E) 
capacitance, and (F) time constant (Tau) between neurons from control and KD mice. (G) Representative traces of membrane potential responses (upper traces) of 
control and KD neurons evoked by a 0.20-nA current step (lower trace). (G) Input-output relationship reflecting the excitability of neurons from control and KD mice. 
(H) Steady-state current-voltage relationship of neurons from control and KD mice recorded in the presence of tetrodotoxin (0.5 μM). The data are presented as the 
mean ± SEM, and no statistically significant differences were revealed between examined neurons. 
Table 1 
Action potential parameters of nucleus accumbens core neurons expressing D1 
receptors from control and Oprd1/Oprm1D1− KD (KD) mice.  
Parameter Control n = 22 KD n = 20 
Threshold [mV] − 44.33 ± 0.64 − 43.75 ± 0.63 
10-90 Rise [ms] 0.33 ± 0.02 0.32 ± 0.01 
Amplitude [mV] 73.28 ± 1.32 73.50 ± 1.52 
Half width [ms] 1.09 ± 0.05 1.05 ± 0.04 
AHP minimum [mV] − 55.73 ± 0.60 − 57.02 ± 0.76 
Peak to AHP [ms] 23.32 ± 1.74 23.61 ± 1.52  
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evoked a reduced effect in KD cells (whole-cell current change: 14 ± 6 
pA) in comparison with control neurons (whole-cell current change: 28 
± 6 pA), but the difference did not reach statistical significance (t(21) =
1.686, p = 0.107; Fig. 4F). 
To confirm the knockdown efficiency of delta opioid receptors in D1- 
expressing cells, D1 striatal neurons from Oprd1/Oprm1D1− KD and con-
trol mice were voltage clamped at − 65 mV, and their responsiveness to 
the selective delta opioid receptor agonist DPDPE (1 μM) was recorded 
(Fig. 5A, B, C, D). We found that all examined neurons from KD mice 
were insensitive to the delta opioid receptor agonist, which was 
confirmed by subsequent statistical analysis (mean whole-cell current at 
baseline: 0.26 ± 0.02 nA; mean whole-cell current during DPDPE 
application: 0.26 ± 0.02 nA; t(9) = 0.1545, p = 0.881). At the same 
time, in neurons from the control mice, bath application of the drug 
generated a reversible, greater than the baseline current value by three 
standard deviations, outward current in 7 of 10 recorded cells (Fig. 5E), 
and the change in the whole-cell current of all examined cells was sta-
tistically significant (mean whole-cell current at baseline: 0.30 ± 0.02 
nA; mean whole-cell current during DPDPE application: 0.31 ± 0.03 nA 
during DPDPE application; t(9) = 4.139, p = 0.0025). Moreover, the 
DPDPE-evoked change in the whole-cell current of D1 striatal neurons 
was significantly different between control and KD neurons (change in 
Fig. 4. Influence of the mu opioid agonist DAMGO 
on the whole-cell current of D1 receptor-expressing 
striatal neurons. (A) A representative voltage-clamp 
recording showing DAMGO (1 μM, horizontal line)- 
induced outward whole-cell currents in control neu-
rons and (B) a corresponding line graph showing the 
DAMGO-induced current amplitude. (C) A representa-
tive voltage-clamp recording showing that neurons 
from KD mice did not respond to DAMGO application 
and (D) a corresponding line graph showing the current 
amplitudes recorded at baseline and during DAMGO 
application. Note the lack of differences between 
whole-cell current amplitudes in the tested conditions. 
(E) Pie charts showing the proportion of DAMGO- 
responsive (filled) and DAMGO-nonresponsive 
(empty) neurons from control and KD mice. (F) The 
amplitudes of DAMGO-induced outward whole-cell 
currents recorded in neurons from control and KD 
mice. The filled circles represent neurons in which the 
change in current in response to DAMGO was greater 
than three standard deviations from baseline. The data 
are presented as the mean ± SEM. Significant differ-
ences between group means (Student’s t-test) are rep-
resented by *** (p < 0.001).   
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the whole-cell current in control neurons: 7 ± 2 pA; change in the whole- 
cell current in KD neurons: 0.2 ± 1.1 pA; t(18) = 3.411, p = 0.003; 
Fig. 5F). 
3.3. General phenotype of Oprd1/Oprm1D1− KD mice 
First, we assessed the behavior of mutant mice in an open field test. 
The mutation targeted striatal neurons of the direct pathway, which may 
have an effect on motor activity. Oprd1/Oprm1D1− KD mice showed a 
normal latency to leave the square in the open field test (Fig. 6A, t(40) =
0.562, p = 0.578), indicating no deficit in movement initiation. There 
was a trend towards a shorter total distance traveled by mutant mice 
compared to wild-type littermates, but this difference did not reach 
significance (t(40) = 1.7, p = 0.097; Fig. 6B). These results indicate no 
appreciable motor impairments that could confound the interpretation 
of the observed behaviors. 
Next, we tested anxiety-like behaviors in the light-dark box and 
during social interaction tests. Oprd1/Oprm1D1− KD mice did not differ 
from wild-type controls in the latency to enter the lit compartment (t 
(16) = 0.915, p = 0.928; Fig. 6C) and overall spent a similar amount of 
time on the lit side (t(16) = 0.622, p = 0.543; Fig. 6D). There was no 
effect of genotype on the number of crossings between compartments 
(control: 11.45 ± 2.31; Oprd1/Oprm1D1− KD: 11.71 ± 2.47; p = 0.945). 
We performed a social interaction test, another test for altered anxiety- 
like behavior, in the open field apparatus. Oprd1/Oprm1D1− KD mice 
spent as much time in proximity with an unfamiliar adult conspecific as 
Fig. 5. The influence of the delta opioid agonist 
DPDPE on the whole-cell current of D1 receptor- 
expressing striatal neurons. (A) A typical voltage- 
clamp recording showing DPDPE (1 μM, horizontal 
line)-induced outward whole-cell currents in control 
neurons and (B) a corresponding line graph showing the 
DPDPE-induced current amplitude. (C) A representative 
voltage-clamp recording showing that neurons from KD 
mice did not respond to DPDPE application and (D) a 
corresponding line graph showing the current amplitude 
recorded at baseline and during DPDPE application. 
Note the lack of differences between whole-cell current 
amplitudes in the tested conditions. (E) Pie charts 
showing the proportion of DPDPE-responsive (filled) 
and DPDPE-nonresponsive (empty) neurons from con-
trol and KD mice. (F) The amplitudes of DPDPE-induced 
outward whole-cell currents recorded in neurons from 
control and KD mice. The filled circles represent neurons 
in which the change in current in response to DPDPE 
was greater than three standard deviations from base-
line. The data are presented as the mean ± SEM. Sig-
nificant differences between group means (Student’s t- 
test) are represented by ** (p < 0.01).   
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Fig. 6. Locomotor activity, anxiety and social in-
teractions in Oprd1/Oprm1D1-KD mice. (A) Initiation 
of movement. The graph shows the latency for each 
mouse to leave a 17 × 17-cm square surrounding its 
initial position. (B) Total distance moved during the 
open field test. (C) Latency to enter the lit compartment 
during the light-dark box test. A latency of 300 s in-
dicates that the animal never left the dark part of box. 
(D) Time spent in the lit compartment. (E) Time spent 
in proximity to an unfamiliar conspecific or inanimate 
object during the interaction test (less than 8 cm be-
tween body centers). In all graphs, each point repre-
sents a single animal, while the bars and whiskers 
correspond to the means ± SEMs.   
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their wild-type littermates and spent significantly more time interacting 
with another mouse than an inanimate object (genotype: F(1,38) =
1.487, p = 0.23; animal vs. object: F(1,38) = 110.8, p < 0.0001; animal 
vs. object x genotype: F(1,38) = 1.66, p = 0.2015; Fig. 6E). Together, 
these results indicate that the mutation did not alter anxiety-like be-
haviors, indicating that its effects were different from the reported ef-
fects of the complete inactivation of the Oprd1 gene (Filliol et al., 2000) 
or treatment with a delta opioid receptor agonist (Perrine et al., 2006). 
3.4. Reward-conditioned behaviors in Oprd1/Oprm1D1− KD mice 
To assess the effects of the mutation on reward sensitivity, we used 
two paradigms: the saccharin preference test and morphine – or social – 
conditioned place preference. First, we measured the volume of 
saccharin-sweetened water (0.1% w/v) consumed by male Oprd1/ 
Oprm1D1− KD and wild-type mice over a period of 24 h in a two-bottle 
choice task. Mutant mice did not differ from wild-type animals in pref-
erence for sweet taste (t(8) = 1.479, p = 0.177; Fig. 7A) or the total 
volume of 0.1% saccharin solution consumed (t(8) = 0.118, p = 0.909; 
Fig. 7B). Next, we subjected female Oprd1/Oprm1D1− KD and wild-type 
mice to a delay discounting task with saccharin as a reward. The main 
advantage of this method is that it is able to detect even a minor dif-
ference in subjective reward value and the propensity for impulsive 
choices. The test was conducted in IntelliCages in which a group of 12 
female mice implanted with radiofrequency identification (RFID) chips 
were housed together for 34 days. Oprd1/Oprm1D1− KD mice showed 
similar general activity as control animals, which decreased slightly but 
significantly over the course of the experiment (number of corner visits, 
time: F(14,140) = 5.783, p < 0.0001; genotype: F(14,140) = 1.438, p =
0.258; time x genotype: F(14,140) = 0.28, p = 0.995; Fig. 7C). The 
mutation had no effect on initial preference for the saccharin solution 
and did not affect the rate of discounting with increasing delay to access 
the reward (time: F(14, 140) = 99.75, p < 0 0.0001; genotype: F (1, 10) 
= 0.245, p = 0.636; time x genotype: F(14, 140) = 0.159, p = 0.9; 
Fig. 7D). There were no differences in the volume of water (time: F(14, 
140) = 88.51, p < 0.0001; genotype: F(1, 10) = 0.005, p = 0.943; time x 
genotype: F(14, 140) = 0.190, p = 0.999; Fig. 7E) or saccharin solution 
(time: F(14, 140) = 94.72, p < 0.0001; genotype: F(1, 10) = 0.733, p =
0.412; time x genotype: F(14, 140) = 0.361, p = 0.983; Fig. 7F) consumed. 
Thus, we found that the mutation did not affect preference for, intake of 
or motivation to drink the saccharin solution. 
Next, we tested morphine-conditioned place preference (CPP). Both 
wild-type and Oprd1/Oprm1D1− KD mice showed an increase in prefer-
ence for the context paired with morphine injections (10 mg/kg, i.p.; 
pre-post: F(1,17) = 45.41 p < 0.0001; genotype: F(1,17) = 1.748 p =
0.204; pre-post x genotype: F(1,17) = 0.278 p = 0.605; post hoc Sidak’s 
test; wt: p = 0.0003; KD: p = 0.0004; Fig. 7G). Mutant mice had, on 
average, slightly lower locomotor activity (particularly during the 
posttest); however, this effect did not reach significance (pre-post: F 
(1,17) = 0.0006, p = 0.989; genotype: F(1,17) = 3.316, p = 0.0862; pre- 
post x genotype: F(1,17) = 1.07, p = 0.316; Fig. 7H). The results showed 
no appreciable effects of receptor knockdown on morphine reward, 
which is consistent with previously reported normal CPP in animals with 
selective deletion of the mu receptor in forebrain GABAergic neurons 
(Charbogne et al., 2017). 
Finally, we tested the rewarding effects of social contact using the 
conditioned place preference paradigm (Fig. 8A). Both mutant and 
control mice acquired a preference for the context associated with group 
housing (pre-post: F(1,13) = 21.1, p = 0.0005; genotype: F(1,13) =
1.54, p = 0.237; interaction: F(1,13) = 0.195, p = 0.666; post hoc 
Sidak’s test; wt: p = 0.009; KD: p = 0.019; Fig. 8B). Motor activity was 
not affected by genotype, although animals from both groups exhibited 
an increase in activity from the pretest to the posttest (pre-post: F(1,13) 
= 19.73, p = 0.0007; genotype: F(1,13) = 2.9, p = 0.11; interaction: F 
(1,13) = 0.054, p = 0.82; post hoc Sidak’s test; wt: p = 0.026; KD: p =
0.009; Fig. 8C). These results showed that the mutation did not 
appreciably affect the rewarding effects of social contact. We attribute 
the genotype-independent change in activity to the normal physical 
development of young animals. 
4. Discussion 
We found that knocking down mu and delta opioid receptors in D1- 
expressing neurons had no appreciable effects on sensitivity to rewards 
or motivation to obtain them. The only changes in behavior were al-
terations in motor activity in some of the tasks that included rewards. 
These results do not completely exclude the involvement of the mu and 
delta opioid receptors present on neurons expressing dopamine receptor 
D1 in reward processing but suggest that they are not an essential part of 
the associated mechanism. 
First, it should be stressed that the mutation utilized in this study 
targets neurons expressing dopamine receptor D1, which is a broader 
group of neurons than a subset of nucleus accumbens or striatal medium 
spiny neurons that prominently includes glutamatergic neurons in lower 
cortical layers. We note, however, that knockdown efficiency is depen-
dent on gene promoter activity, and D1 expression is several-fold higher 
in medium spiny neurons than in other cell types (Nam et al., 2019). 
Accordingly, immunofluorescence staining of GFP in the striatum 
appeared considerably stronger than in other areas. No significant 
behavioral effects of knockdown were observed, which could indicate 
that opioid signaling in nonstriatal cells also has no essential role in 
reward-driven behaviors. However, it is likely that knockdown in cells 
other than medium spiny neurons was less efficient and that mu and 
delta opioid receptor signaling was thus spared. Furthermore, analysis of 
Oprm1 and Oprd1 transcript levels yielded a partly unexpected result. 
The abundance of the Oprm1 transcript was reduced to an extent that is 
similar to the proportion of cells targeted (~35%), but Oprd1 mRNA 
levels were not reduced. This may suggest that the largest Oprd1 
expression occurs in nontargeted cells, although we may not exclude the 
possibility that the knockdown affected translation rather than tran-
scription. Nevertheless, analysis of the transcript levels could mean that 
most mu and delta opioid receptors are still present in the striatum of 
Oprd1/Oprm1D1− KD mice. 
We showed that under ex vivo conditions, the majority of D1- 
expressing striatal medium spiny neurons from control mice were sen-
sitive to mu and delta receptor agonists. The coexpression of D1 and 
delta opioid receptors has been previously reported in striatal neurons 
(Ambrose et al., 2006; Ma et al., 2012). Here, we confirmed these data 
and showed that delta opioid receptor stimulation in D1-expressing 
neurons activated outward whole-cell currents, which correspond to 
the hyperpolarization of the cell membrane. To the best of our knowl-
edge, the presented results are the first to show the direct, inhibitory 
effect of opioid receptor activation on whole-cell currents in striatal 
neurons. Notably, in knockdown mice, the mutation led to the complete 
loss of sensitivity to the delta opioid receptor agonist (DPDPE). These 
results not only confirm knockdown but also, along with results ob-
tained in ACSF in the presence of tetrodotoxin, are proof of the presence 
of delta opioid receptors on the postsynaptic membrane of the majority 
of striatal D1-receptor-expressing neurons. Similarly, most of the tested 
control cells were sensitive to the mu opioid receptor agonist DAMGO, 
and the selective activation of mu receptors also led to outward current 
activation. D1 and mu opioid receptor coexpression in the striatum is 
well documented (Cui et al., 2014; Oude-Ophuis et al., 2014), and its 
hyperpolarizing influence is attributed to postsynaptic action (Elghaba 
and Bracci, 2017). Again, the lack of response of knockdown mice to the 
agonists allows us to conclude that the functional mu opioid receptor is 
largely absent in mutant animals. Notably, some reports indicate that 
there is a large fraction of “spare” opioid receptors, and in some cases, 
10% of total receptors could be sufficient to produce a full response after 
activation with an agonist (Chavkin and Goldstein, 1984). Accordingly, 
DAMGO may exert its full effects after activating only a fraction of the 
receptors (Robinson et al., 2015). We are unsure if the effects of DAMGO 
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Fig. 7. Reward sensitivity in Oprd1/Oprm1D1-KD mice. (A) 
Preference for a 0.1% saccharin solution over water in the 
two-bottle test. (B) Total volume of the saccharin solution 
consumed over the duration of the test (24 h). The bars and 
whiskers correspond to the means ± SEMs. (C) Activity in the 
IntelliCage during the delay-discounting test. The graph shows 
the mean number of visits per animal per 24-h period. The x 
axis shows the delay of access to reward. The error bars 
represent the SEMs. (D) Mean preference for a 0.1% saccharin 
solution over water during the delay-discounting procedure. 
(E, F) Mean number of licks of a water bottle and a saccharin 
bottle per 24 h. (G) Time spent in the morphine-paired 
compartment before (pre) and after (post) conditioning. 
Each pair of points connected by a line corresponds to an in-
dividual animal. (H) Motor activity in the apparatus before 
(pre) and after (post) conditioning. Activity was scored each 
time an animal crossed one of the infrared beams in the 
compartments. Significant differences between sample means 
(Sidak’s test) are represented by *** (p < 0.001).   
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or DPDPE on inwardly rectifying current on medium spiny neurons are 
also associated with a reserve pool of spare receptors; nevertheless, if 
that was the case, then the efficiency of the knockdown would be greater 
than the effect observed by electrophysiology. One caveat that should be 
mentioned is that since the DPDPE-evoked currents were relatively 
small, it was more difficult to detect reduced currents after knockdown. 
Thus, the possibility that the effective knockdown in cases of mu and 
delta was similarly incomplete should not be excluded. Finally, the lack 
of either mu or delta receptors did not change the passive or active 
membrane properties of D1-expressing neurons; therefore, any behav-
ioral effect of the mutation can be attributed to altered opioid signaling, 
not the dysfunction of D1-expressing neurons. 
The normal preference for sweet taste and morphine- or social- 
conditioned place preference observed in KD animals were unex-
pected. Based on the reported role of opioid signaling in the “liking” 
component of reward, we anticipated a decrease in sweet taste prefer-
ence or possibly reduced consumption of sweetened water (Castro and 
Berridge, 2014; Peciña and Berridge, 2005). We also hypothesized that 
the loss of mu and delta receptors would affect the rewarding effects of 
social contact, but we found no evidence of any social impairments. We 
were uncertain whether knockdown could affect motivation (i.e., delay 
discounting) or the rewarding effects of morphine and found them to be 
unaltered. The simplest explanation for the normal phenotypes is that 
knockdown allowed sufficient opioid receptor activity to sustain 
reward-driven behaviors. Nevertheless, we find this possibility unlikely, 
as behavioral changes have been reported after antagonist treatment, 
which is unlikely to completely block receptor function. Alternatively, it 
can be argued that opioid receptors in other types of striatal neurons 
play the primary and essential role in reward-driven behaviors. How-
ever, this may be inconsistent with the reported role of D1-expressing 
neurons in mediating the reinforcing effects of rewards (e.g. Calipari 
et al., 2016; Cole et al., 2018; Kravitz et al., 2012). Moreover, this 
assumption might be counterintuitive in the context of the reported 
rescue of morphine-conditioned place preference in mice with Oprm1 
gene KO by the reintroduction of mu receptors in Pdyn-expressing cells 
(i.e., mainly direct pathway medium spiny neurons in the nucleus 
accumbens (Cui et al., 2014)). One way to reconcile these reports and 
the observed phenotypes is to assume redundancy in the roles played by 
opioid signaling in different types of medium spiny neurons and through 
presynaptic receptors. Thus, opioid receptors on dopamine neurons 
lacking D1 receptors or on presynaptic terminals could possibly 
compensate for the effects of knockdown. Opioid receptors have pri-
marily inhibitory effects on transmission, and their activation in any 
part of the network that drives activity, such as delta receptors on 
excitatory neurons in the cortex or mu and delta receptors on cholinergic 
neurons, could have similar effects. This is speculative and immediately 
raises the question of why redundancy in opioid system functions could 
be necessary. Hypothetically, this could be associated with separate 
control of desensitization of opioid receptors in different cell types 
and/or the existence of opioid receptor pools with high or low affinities 
for endogenous ligands (Pasternak and Pan, 2013). This could be further 
extended to a proposed different efficiency of inhibition mediated by mu 
and/or delta receptors located at different sites in the signaling pathway. 
However, these ideas remain a speculation, and further investigation is 
necessary to confirm whether such effects may actually be observed. 
5. Conclusions 
We found that mu and delta receptors are ubiquitously present in D1- 
expressing medium spiny neurons but are not essential for the control of 
signaling underlying reward-driven behaviors. 
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Jastrzębska, K., Walczak, M., Cieślak, P.E., Szumiec, Ł., Turbasa, M., Engblom, D., 
Błasiak, T., Rodriguez Parkitna, J., 2016. Loss of NMDA receptors in dopamine 
neurons leads to the development of affective disorder-like symptoms in mice. Sci. 
Rep. 6, 37171. 
Kravitz, A.V., Tye, L.D., Kreitzer, A.C., 2012. Distinct roles for direct and indirect 
pathway striatal neurons in reinforcement. Nat. Neurosci. 15, 816–818. 
Kupchik, Y.M., Brown, R.M., Heinsbroek, J.A., Lobo, M.K., Schwartz, D.J., Kalivas, P.W., 
2015. Coding the direct/indirect pathways by D1 and D2 receptors is not valid for 
accumbens projections. Nat. Neurosci. 18, 1230–1232. 
Le Merrer, J., Becker, J.A.J., Befort, K., Kieffer, B.L., 2009. Reward processing by the 
opioid system in the brain. Physiol. Rev. 89, 1379–1412. 
Ma, Y.-Y., Cepeda, C., Chatta, P., Franklin, L., Evans, C.J., Levine, M.S., 2012. Regional 
and cell-type-specific effects of DAMGO on striatal D1 and D2 dopamine receptor- 
expressing medium-sized spiny neurons. ASN Neuro 4, AN20110063. 
Mansour, A., Fox, C.A., Akil, H., Watson, S.J., 1995. Opioid-receptor mRNA expression in 
the rat CNS: anatomical and functional implications. Trends Neurosci. 18, 22–29. 
Matthes, H.W.D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., 
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